© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Abeona Therapeutics Inc. (ABEO) stock declined over -0.50%, trading at $5.95 on NASDAQ, down from the previous close of $5.98. The stock opened at $5.98, fluctuating between $5.86 and $6.10 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 02, 2026 | 5.98 | 6.10 | 5.86 | 5.95 | 1.09M |
| Sep 01, 2026 | 5.80 | 6.00 | 5.79 | 5.98 | 683.19K |
| Aug 31, 2026 | 5.91 | 5.92 | 5.78 | 5.85 | 993.53K |
| Aug 28, 2026 | 5.99 | 6.04 | 5.88 | 5.92 | 912.58K |
| Aug 27, 2026 | 6.01 | 6.10 | 5.93 | 6.04 | 537.22K |
| Aug 26, 2026 | 6.24 | 6.26 | 6.00 | 6.01 | 1.19M |
| Aug 25, 2026 | 6.14 | 6.32 | 6.14 | 6.21 | 780.04K |
| Aug 24, 2026 | 6.12 | 6.14 | 6.01 | 6.06 | 848.16K |
| Aug 21, 2026 | 6.03 | 6.14 | 6.01 | 6.09 | 889.51K |
| Aug 20, 2026 | 6.06 | 6.17 | 5.95 | 5.96 | 1.22M |
| Aug 19, 2026 | 6.31 | 6.32 | 6.11 | 6.13 | 1.3M |
| Aug 18, 2026 | 5.90 | 6.30 | 5.87 | 6.16 | 1.32M |
| Aug 17, 2026 | 5.86 | 6.02 | 5.70 | 5.94 | 2.09M |
| Aug 14, 2026 | 6.21 | 6.29 | 5.82 | 5.99 | 5.44M |
| Aug 13, 2026 | 6.09 | 6.70 | 6.05 | 6.35 | 4.87M |
| Aug 12, 2026 | 7.40 | 7.55 | 7.31 | 7.46 | 2.21M |
| Aug 11, 2026 | 7.47 | 7.65 | 7.39 | 7.40 | 2.19M |
| Aug 10, 2026 | 7.18 | 7.47 | 7.12 | 7.45 | 1.17M |
| Aug 07, 2026 | 6.97 | 7.30 | 6.94 | 7.24 | 1.4M |
| Aug 06, 2026 | 6.78 | 7.08 | 6.78 | 6.90 | 827.88K |
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
| Employees | 226 |
| Beta | 1.34 |
| Sales or Revenue | $3.50M |
| 5Y Sales Change% | -0.896% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |